Pellegrini Cinzia, Broccoli Alessandro, Pulsoni Alessandro, Rigacci Luigi, Patti Caterina, Gini Guido, Mannina Donato, Tani Monica, Rusconi Chiara, Romano Alessandra, Vanazzi Anna, Botto Barbara, Santoro Armando, Hoaus Stefan, Rigolin Gian Matteo, Musto Pellegrino, Mazza Patrizio, Molica Stefano, Corradini Paolo, Fama Angelo, Gaudio Francesco, Merli Michele, Ronconi Fioravante, Gritti Giuseppe, Vallisa Daniele, Tosi Patrizia, Liberati Anna Marina, Pinto Antonello, Pavone Vincenzo, Gherlinzoni Filippo, Bianchi Maria Paola, Volpetti Stefano, Trentin Livio, Goldaniga Maria Cecilia, Bonfichi Maurizio, De Renzo Amalia, Schiavotto Corrado, Spina Michele, Carella Angelo Michele, Stefoni Vittorio, Argnani Lisa, Zinzani Pier Luigi
Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy.
Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.
一项大型意大利多中心观察性回顾性研究针对复发霍奇金淋巴瘤（HL）患者使用本妥昔单抗（BV）进行，以检查即使在现实生活环境中临床试验结果是否也能得到证实。共纳入234例CD30+ HL患者。140例患者（59.8%）在中位4个周期后观察到最佳反应：74例（31.6%）患者获得完全缓解（CR），66例（28.2%）达到部分缓解（PR）；治疗结束时的总缓解率为48.3%（62例CR和51例PR）。老年亚组的最佳缓解率更高：14例（50%）CR和5例（17.8%）PR。3年无病生存率为26.3%，4.5年无进展生存率为31.9%。对于至少达到PR且随后接受或未接受巩固性移植的患者，缓解持续时间无差异。总体而言，该治疗耐受性良好，尚无死亡与BV诱导的毒性相关。我们的报告证实了BV在老年患者中的活性、缓解持续时间与移植巩固程序无关、首次再分期时CR状态的相关性以及BV作为化疗难治性患者移植桥梁的作用。
